Metaplastic breast carcinoma: Analysis of 31 cases from a single institute

Fayaz, Salah; Demian, Gerges Attia; Eissa, Heba El-Sayed; Amanguno, Henney G.; Abuzalouf, Sadeq

doi:10.1016/j.jnci.2017.05.002

Cited by 12 publications

(26 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, various studies report five-year OS between 65% and 69%. [20,23,27,28] In our study the five-year OS was 76.3%. Both the PFS and OS of our patient population are higher than survivals reported from the West.…”

Section: Discussionsupporting

confidence: 48%

See 1 more Smart Citation

Survival and treatment outcomes of metaplastic breast carcinoma: Single tertiary care center experience in Pakistan

et al. 2019

View full text Add to dashboard Cite

BACKGROUND: Metaplastic breast carcinoma (MBC) is a rare disease with incidence of less than 1%. MBC present with a larger tumor size, less number of nodes involved, mostly undifferentiated triple negative tumors. We aimed to determine progression-free and overall survival and reported hospital-based incidence of MBC. MATERIAL AND METHODS: A retrospective closed Cohort study elicited data of 42 patients with MBC from January 2008 to December 2013; followed till August 2016. Kaplan-Meier method was applied to compute overall and progression-free survival analysis. Cox Proportional hazard ratios were computed to assess associations between survival and independent variables. RESULTS: Hospital-based incidence of MBC was 1.92% (42/2187), 95% CI [1.41-2.56]. The median age at tumor diagnosis was 54 years (range, 25-81 years). Thirty-nine (92.9%) patients had Grade III tumor. The most common histopathology was squamous (69%). The median tumor size was 4.5 cm (range, 0.8-17 cm). Nineteen (45.2%) patients had nodal involvement at diagnosis. Four patients (9.5%) had metastatic disease at presentation. Hormone receptors were positive in 19 (45.2%) patients. Her-2 neu receptor was positive in 9 (19%) patients. Sixteen (38.1%) patients had triple negative disease. Neoadjuvant and adjuvant chemotherapy was received by 10 (31.25%) and 19 (45.2%) patients respectively. Both median progression-free and overall survival was 38 months. CONCLUSION: Five-year progression-free and overall survival was 79.5% and 76.3%, respectively. We report better survival outcomes when compared to series described earlier despite our patient population presenting mostly with high grade, large tumors, and half of them exhibiting nodal and hormonal involvement.

show abstract

Section: Discussionsupporting

confidence: 48%

“…The five-year PFS from International data is reported between 30% and 69%. [23,27,28] We report a five-year PFS of 79.5%. Similarly, various studies report five-year OS between 65% and 69%.…”

Section: Discussionmentioning

confidence: 77%

Survival and treatment outcomes of metaplastic breast carcinoma: Single tertiary care center experience in Pakistan

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Five-year overall survival rates have been estimated to be between 49-69% (5,10,(12)(13)22,35,(37)(38)(39).…”

Section: Discussionmentioning

confidence: 99%

“…The survival of MpBC patients reported in institutional studies is summarised in Table II. In general, MpBC patients experienced greater disease recurrence and poorer overall survival compared to both triple negative IDC and general IDC (10,12,13,(37)(38)(39). Benson et al reported on 7 patients with MpBC from a single institution in India, in which all patients underwent mastectomy followed by PMRT and adjuvant chemotherapy (40).…”

Section: Discussionmentioning

confidence: 99%

Metaplastic carcinoma of the breast: Clinicopathological features and treatment outcomes with long‑term follow up

et al. 2021

View full text Add to dashboard Cite

Metaplastic breast carcinoma is an uncommon subtype of invasive ductal carcinoma with a tendency towards poorer clinical outcomes. Following ethical approval, the current study reviewed the institutional records of ~2,500 women with breast cancer. A total of 14 cases of metaplastic breast cancer were reviewed for management and treatment outcomes. The results demonstrated that patients had median follow up of 30 months, a 5-year disease-free survival of 57.1% and 5-year overall survival of 57.1%. The majority of patients had at least T2 disease and all tumours were high grade. Additionally, most patients were triple negative and nodal metastases were uncommon. Metaplastic breast cancer is an aggressive variant of invasive breast cancer. Most patients can be treated with breast conservation and survival parameters tend to be worse than more common breast cancer subtypes.Subjects. A total of 14 patients with MpBC from our three integrated comprehensive cancer centres who received curative intent radiation therapy between January 2009 and January 2020 were included. Methods.We reviewed age at diagnosis, gender, tumour laterality, tumour size, axillary nodal status, presence of lymphovascular invasion (LVI), histological grade, receptor status [estrogen receptor (ER); progesterone receptor (PR);

show abstract

“…Its outcome has been reported worse compared with invasive ductal carcinoma or triple negative ductal carcinoma. In addition, patients with metaplastic breast carcinoma have a lower rate of pathologic complete response to neoadjuvant chemotherapy [5][6][7].…”

Section: Discussionmentioning

confidence: 99%

Metaplastic Breast Carcinoma: Clinical and Imaging Features

Márquez¹

2018

CRIJ

View full text Add to dashboard Cite

Metaplastic breast carcinoma is a very infrequent type of malignancy (<1% of invasive breast tumors), of poor prognosis and of high histological grade. It is due to a metaplasia of the breast glandular epithelium. There are several types, among which squamous cell carcinoma is the most frequent. The age of presentation is usually in women older than 50 years who report a fast growing tumor. Radiologically they are usually well circumscribed lesions, and if they are of a large volume they can be complicated, with ulceration or fixation to the skin or even to the chest wall. They have a worse prognosis than patients with infiltrating ductal or lobular carcinoma, with an incidence of metastatic disease between 5-30%. We present the case of a 50 years old woman with a palpable mass in the left breast, ulcerated. We show the characteristics of this entity in the different imaging techniques. Finally, an ultrasound biopsy confirmed the diagnosis of metaplastic breast carcinoma.A 50-year-old woman was addressed to the Gynecology department for palpable mass in the left breast. Physical examination shows a mass of approximately 10 cm that affects the entire breast, with areas of ulceration (Figure 1). Figure 1: Ulcerated mass in left breast.

show abstract

Metaplastic breast carcinoma: Analysis of 31 cases from a single institute

Abstract: MBC is a rare entity among breast carcinoma in Kuwait. Most of the cases present with poor prognostic indicators and often show lack of expression of ER, PR and Her2/neu.

Cited by 12 publications

References 23 publications

Survival and treatment outcomes of metaplastic breast carcinoma: Single tertiary care center experience in Pakistan

Survival and treatment outcomes of metaplastic breast carcinoma: Single tertiary care center experience in Pakistan

Metaplastic carcinoma of the breast: Clinicopathological features and treatment outcomes with long‑term follow up

Metaplastic Breast Carcinoma: Clinical and Imaging Features

Contact Info

Product

Resources

About